Spots Global Cancer Trial Database for Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study
Official Title: Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study
Study ID: NCT02782182
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to see whether it is possible to give 8 doses of a combination of chemotherapy called FOLFIRINOX before surgery in subjects whose pancreas cancer can be removed with surgery.
Detailed Description: Primary Objective: To evaluate the percentage of pancreatic cancer patients able to complete the full 4 months of preoperative chemotherapy and undergo a resection. Secondary Objectives * To assess the percentage of patients able to complete all therapy, including preoperative chemotherapy, surgery, and postoperative therapy. * To assess treatment-related toxicity during preoperative therapy * To assess intra-operative and post-operative complications * To assess the histopathologic (R0/R1) resection rate after preoperative therapy * To determine disease free survival (DFS) for patients who undergo resection. * To determine progression free survival (PFS) for all patients * To determine overall survival (OS) from the date of first treatment
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Contact Details
Name: Hedy Kindler, M.D.
Affiliation: University of Chicago
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
